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Abstract: BioXmark® (Nanovi A/S, Denmark) is a novel fiducial marker based on a liquid, iodine-based
and non-metallic formulation. BioXmark® has been clinically validated and reverse translated to
preclinical models to improve cone-beam CT (CBCT) target delineation in small animal image-guided
radiotherapy (SAIGRT). However, in phantom image analysis and in vivo evaluation of radiobiological
response after the injection of BioXmark® are yet to be reported. In phantom measurements were
performed to compare CBCT imaging artefacts with solid fiducials and determine optimum imaging
parameters for BioXmark®. In vivo stability of BioXmark® was assessed over a 5-month period, and
the impact of BioXmark® on in vivo tumour response from single-fraction and fractionated X-ray
exposures was investigated in a subcutaneous syngeneic tumour model. BioXmark® was stable, well
tolerated and detectable on CBCT at volumes ≤10 µL. Our data showed imaging artefacts reduced by
up to 84% and 89% compared to polymer and gold fiducial markers, respectively. BioXmark® was
shown to have no significant impact on tumour growth in control animals, but changes were observed
in irradiated animals injected with BioXmark® due to alterations in dose calculations induced by the
sharp contrast enhancement. BioXmark® is superior to solid fiducials with reduced imaging artefacts
on CBCT. With minimal impact on the tumour growth delay, BioXmark® can be implemented in
SAIGRT to improve target delineation and reduce set-up errors.
Keywords: small animal image-guided radiotherapy; fiducial markers; radiation response
1. Introduction
Radiotherapy is a major modality in the radical treatment of cancer, being prescribed to >50% of
patients during their treatment [1]. In recent decades, significant advances in radiotherapy technology
have enabled increasingly sophisticated, conformal delivery methods to be implemented into routine
clinical practice, such as intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy
(VMAT) and stereotactic body radiotherapy (SBRT) [2–4]. The success of high-precision radiotherapy
techniques is predicated on the use of volumetric imaging methods at all stages of the treatment
process, from planning, delivery and verification to follow-up. Parallel developments in small
animal image-guided radiotherapy (SAIGRT) platforms presents the opportunity to closely mimic
clinical scenarios and further radiobiological understanding of tumour and normal tissue response [5].
Although these platforms increase the ability to irradiate small target volumes in vivo with the highest
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precision and accuracy to date, there is scope for improvement of soft tissue imaging and treatment
alignment parameters.
Several imaging modalities have been used to optimise treatment positioning accuracy and
precision, including megavoltage planar imaging, static kilovoltage planar imaging, ultrasound, cone
beam CT (CBCT) and portal imaging [6–8]. However, these methods have limited soft-tissue contrast,
which has driven the recent integration of magnetic resonance imaging (MRI) with linear accelerators
(Linac) in the MR-Linac Radiotherapy Systems. These systems have the potential to exploit the benefits
of MRI with real-time motion management and adjustment on a patient-specific basis [9]. The clinical
benefits of MRI-guided radiotherapy remain to be fully demonstrated, and it is unlikely this approach
will be widely implemented into routine practice for most tumours in the short term.
Currently, solid fiducial markers are FDA-approved and used in clinical practice to improve the
visualization of low-contrast tissues and reduce uncertainties in set-up and targeting [10–15]. However,
solid fiducial markers can negatively impact CT and MRI due to differences in image artefacts and
contrast enhancement [16–20]. Furthermore, imaging artefacts may increase the dosimetric error
during treatment planning and are a particular concern in proton therapy [21,22].
Recently, a novel liquid fiducial marker, BioXmark®, was developed and demonstrated to
produce fewer imaging artefacts in multiple imaging modalities [16,18,22,23]. BioXmark® was been
applied to preclinical imaging studies in an orthotopic pancreatic tumour model and in phantom
measurements [23–25]. There is further scope to increase precision and accuracy in SAIGRT studies
and to improve animal welfare within the framework of the National Centre for the Replacement,
Refinement and Reduction of Animals in Research (NC3Rs) [26–28].
The purpose of this study was to compare image contrast and artefacts of BioXmark® with current
solid fiducial markers used for preclinical CBCT imaging applications. We also aimed to determine the
stability of BioXmark® and evaluate its impact on tumour response in vivo.
2. Results
2.1. In Phantom Studies
Imaging artefacts can be defined as discrepancies in CBCT scans that are not present in the object
under investigation and degrade the quality of the image. These reduce the visualisation of structures
through streaks, lines and shadows [29]. Imaging artefacts following CBCT were determined at energies
of 40, 50 and 60 kV (0.5 mm Al filtration) for BioXmark® and two clinically used solid fiducial markers
(Figure 1A). Fiducials were placed in a 3D-printed box which was filled with gelatine to replicate soft
tissue density. All three fiducials were easily visualised on CBCT at each of the energies investigated,
which are typically used during small animal imaging (40–60 kV). CBCT numbers ranging between
12,000 and 33,000 were detected across all three of the markers investigated. CBCT numbers for the
solid fiducials were 40%–53% (p < 0.001) higher than those detected for BioXmark® (Figure 1B), which
indicated a higher X-ray attenuation [30]. Imaging artefacts showed a distinct energy dependence,
with the lowest imaging artefacts for all fiducial markers observed at 60 kV. Comparing energies of
40 kV and 60 kV, there were reductions of 12% (p = 0.61), 37% (p = 0.12) and 66% (p < 0.001) of imaging
artefact area for gold, polymer and BioXmark®, respectively (Figure 1C,D). Overall, imaging artefacts
across all energies caused by BioXmark® were significantly lower than both of the solid markers, with
a reduction of 89% (p < 0.001) and 84% (p < 0.001) imaging artefact area compared to gold and polymer
fiducials at 60 kV. Although the solid fiducial markers had good contrast enhancement, the observed
increase in imaging artefacts compared to BioXmark® negatively impacted the imaging of anatomical
structures, which is important during SAIGRT.
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Figure 1. In phantom analysis of CBCT visibility and imaging artefacts for BioXmark® and solid 
fiducial markers. (A) Representative imaging of BioXmark® (20 µL), polymer and gold fiducial 
markers and corresponding CBCT numbers at imaging energies of 40, 50 and 60 kV (B). (C) Analysis 
of imaging artefacts on CBCT images processed using ImageJ and presented at imaging energies of 
40, 50 and 60 kV (D). Data presented are mean values ± standard error (SEM); statistical significance 
is reported as * > 0.05, ** > 0.01, *** 0.0001, **** > 0.0001. 
To further analyse CBCT imaging artefacts, multiple volumes of BioXmark® were compared 
using the same in phantom set-up (Figure 2). Figure 2A shows the CBCT images for volumes of 
BioXmark® from 10 to 60 µL, which are more suitable for SAIGRT. All volumes were easily visualised 
with minimal difference in CBCT values (Figure 2B); a minor fluctuation of 2.0% ± 2.4% was seen 
between 40 kV and 50 kV for 20 µL. Imaging artefacts were shown to positively correlate with the 
volume of BioXmark® (Figure 2C,D). However, the observed imaging artefacts at the largest volume 
of 60 µL were substantially lower than those for the solid markers, which had a comparable volume 
of 0.4–2.4 µL. These data are consistent with observations from previous studies which concluded 
that volumes of BioXmark® >50 µL produce hardening imaging artefacts in vivo, making it unsuitable 
for SAIGRT [24]. Our results suggest that volumes >60 µL produce imaging artefacts comparable to 
that of solid fiducial markers, whilst smaller volumes (10 and 20 µL) can effectively enhance CBCT 
image contrast enhancement by at least 50% with minimal surrounding imaging artefacts. These data 
support and define key parameters for the application of BioXmark® in SAIGRT. 
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Figure 2. In phantom analysis of CBCT visibility and imaging artefacts for multiple volumes of 
BioXmark®. (A) Representative imaging of 10, 20, 40 and 60 µL of BioXmark® on CBCT at 40, 50 and 
60 kV. CBCT scans were taken twice at each energy. Corresponding CBCT numbers at imaging 
energies of 40, 50 and 60 kV (B). Analysis of imaging artefacts were processed on ImageJ (C) and 
quantified (D). Data presented are mean values ± SEM; statistical significance is reported as * > 0.05, 
** > 0.01. 
2.2. In Vivo Stability 
We tested the long-term stability of BioXmark® in vivo with longitudinal CBCT imaging analysis 
over a 5-month period following subcutaneous and intraperitoneal injection. Figure 3 shows the 
CBCT values, volume of BioXmark® and body weights of mice throughout the duration of the study. 
Body weight, body score conditioning and the behaviour of mice was normal, with BioXmark® not 
having an effect on the viability of the mice (Figure 3B). BioXmark® was easily observable on CBCT 
and maintained a high CBCT value for each volume, with no significant marker degradation evident 
up to 5 months post-injection in either subcutaneous or intraperitoneal models (Figure 3A). 
The observed volumes of BioXmark® showed a small decrease after injection but then remained 
stable for the remainder of the study, with minimal tissue migration seen on CBCT scans (Figure 3C–
E). This was expected due to the efflux of the solvent, ethanol, causing an immediate decrease in 
marker volume [31]. An average decrease in volume of 13% (p = 0.40), 16.1% (p = 0.35) and 17.5% (p = 
0.17) was detected 14 days post-injection for 10 µL, 20 µL and 40 µL, respectively. 
Volume changes were monitored after a subcutaneous or intraperitoneal injection of 40 µL 
(Figure 3D). Higher stability was apparent in the subcutaneous injection due to insignificant marker 
migration and constant volume. Although the volume of BioXmark® decreased after intraperitoneal 
injection, the volume was stable with no decrease in marker volume for the remainder of the study. 
In agreement with previously published reports, 10 µL was found to be the smallest volume that 
could be reproducibly injected [24]. 
Migration of subcutaneously injected markers was visually assessed from CBCT scans and 
quantified from a defined reference points in the spine. All volumes were shown to be stable with all 
movements being less than 2 mm (Figure 3E). 
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2.2. In Vivo Stability
We tested the long-term stability of BioXmark® in vivo with longitudinal CBCT imaging analysis
over a 5-month period following subcutaneous and intraperitoneal injection. Figure 3 shows the CBCT
values, volume of BioXmark® and body weights of mice throughout the duration of the study. Body
weight, body score conditioning and the behaviour of mice was normal, with BioXmark® not having
an effect on the viability of the mice (Figure 3B). BioXmark® was easily observable on CBCT and
maintained a high CBCT value for each volume, with no significant marker degradation evident up to
5 months post-injection in either subcutaneous or intraperitoneal models (Figure 3A).
The observed volumes of BioXmark® showed a small decrease after injection but then remained
stable for the remainder of the study, with minimal tissue migration seen on CBCT scans (Figure 3C–E).
This was expected due to the efflux of the solvent, ethanol, causing an immediate decrease in marker
volume [31]. An average decrease in volume of 13% (p = 0.40), 16.1% (p = 0.35) and 17.5% (p = 0.17)
was detected 14 days post-injection for 10 µL, 20 µL and 40 µL, respectively.
Volume changes were monitored after a subcutaneous or intraperitoneal injection of 40 µL
(Figure 3D). Higher stability was apparent in the subcutaneous injection due to insignificant marker
migration and constant volume. Although the volume of BioXmark® decreased after intraperitoneal
injection, the volume was stable with no decrease in marker volume for the remainder of the study.
In agreement with previously published reports, 10 µL was found to be the smallest volume that could
be reproducibly injected [24].
Migration of subcutaneously injected markers was visually assessed from CBCT scans and
quantified from a defined reference points in the spine. All volumes were shown to be stable with all
movements being less than 2 mm (Figure 3E).
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Intraperitoneal injection led to movement of the marker throughout the peritoneal cavity; this may
have been due to the marker accumulating in small volumes at different areas (Figure S1).
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2.3. In Vivo Tumour Model
C57BL/6 mice subcutaneously implanted with Lewis lung carcinoma (LLC) tumours were
monitored (weight and tumour volume) three times weekly (Figure 4). Mice weights within each
treatment group showed minor fluctuations but remained within a tolerable weight loss of <15%
(Figure 4A). At tumour volumes of 100 mm3, mice were randomly assigned to treatment groups as
defined in the Materials and Methods. A previous preclinical study with BioXmark® demonstrated
a successful orthotopic injection of the marker after the tumour had grown to a treatable size [24].
Although, clinically, fiducial markers are usually placed in tissue surrounding a tumour, our study
aimed to evaluate radiobiological response of BioXmark® on tumour tissue; therefore, we completed
intratumoral injections for beam targeting. BioXmark® was not injected with the tumour cells as
this was deemed unfeasible due to a high viscosity and semi-hydrophobic composition in a previous
study [24]. Once the tumours were established at a pre-treatment volume of 100 mm3, BioXmark® was
injected intratumorally. We suspected no uptake of the marker into tumour cells, but a small volume
of cells would be surrounded by BioXmark®. Treatment plans for subgroups without an intratumoral
injection of BioXmark® were targeted to the central point of the tumour.
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Control animals had rapidly growing proliferative tumours which were not significantly impacted
by intratumoral injection of BioXmark® and reached maximum tumour volume within 10 days
(p = 0.55). After a single fraction of 16 Gy, both control and BioXmark®-injected animals showed an
average tumour growth delay of 15 days (p = 0.95) indicating that BioXmark® had no significant
impact on tumour response. In contrast, the fractionated treatment groups of 2 × 8 Gy and 4 × 4 Gy
showed different tumour growth delay characteristics, with the BioXmark®-injected tumours showing
reduced tumour growth delay compared to control irradiated tumours (Figure 4B).
Dose volume histograms (DVH) extracted from the treatment planning software, Muriplan,
showed that injection of BioXmark® affected the dose calculations by producing imaging artefacts
which reduced the actual dose delivered to the irradiated tumours (Figure 5), with the CBCT values for
all materials involved presented in Table S1. Treatment planning software detected the high density of
BioXmark®, equivalent to bone, which led to the calculation of a lower dose.
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Consequently, tumours containing BioXmark® repeatedly received a lower dose than irradiated
control animals and so the fractionated treatment groups had been underdosed; this effect became
important with the increase in the number of fractions delivered. The effects were more significant for
fractionated doses due to a lower biological effective dose (BED) compared to single-dose exposures
(Table 1).
Table 1. Summary of treatment parameters following single-fraction and fractionated radiotherapy
exposures in combination with BioXmark®. Base on the I in vitro dose response of LLC cells, an α/β
ratio of 3.1 was used to calculate the BED and EQD2. Treatment plans (Muriplan software, Xstrahl
Inc, Suwannee, GA, USA) were used to calculate the total dose delivered; an average of six mice were
allocated to each subgroup and results were averaged.
Dose Schedule BED (Gy) EQD2 (Gy)
Average Total
Dose Delivered
(cGy ± SEM)
Difference in
Dose Compared to
Non-BioXmark®
Control (%)
4 × 4 Gy
36.6 22.3
1609 ± 7
4 × 4 Gy + BioXmark® 1442 ± 113 −10.4
2 × 8 Gy
57.3 34.8
1606 ± 8
2 × 8 Gy + BioXmark® 1254 ± 153 −21.9
16 Gy
98.6 59.9
1611 ± 14
16 Gy + BioXmark® 1307 ± 160 −18.8
Retrospective analysis was undertaken through replanning the beam isocentres and determining
the updated dose calculations for BioXmark® treatment groups. Initial treatment plans used BioXmark®
as the isocentre placement for beam orientation, whereas for the second round of planning, this was
used for guidance only, with the isocentre placed adjacent to the injected BioXmark®. Movement of
the isocentre millimetres away from the injected BioXmark® lead to an even dose distribution to the
tumour, and thus the DVHs produced from this replanning resulted in a recalculated dose similar to
the dose delivered to the irradiated only animals and the prescribed dose (Figure S2).
3. Discussion
In this study, we evaluated the performance of BioXmark® as an injectable liquid fiducial marker
for imaging applications on small animal radiotherapy platforms. SAIGRT is the current state-of-the-art
technology in experimental radiobiology, and is enabling previously unachievable approaches to
closely mimic clinical exposure scenarios in laboratory studies [5,32–34]. In these systems, onboard
CBCT imaging can potentially deliver volumetric imaging of soft tissues, yet there remain considerable
challenges associated with delineation of soft tissues, targeting of small volumes and standardisation
of imaging and treatment planning set-ups that vary between laboratories [28,32,35,36].
Solid fiducial markers have clinically proven to be beneficial in treatment targeting and alignment,
but have not reverse-translated into preclinical applications due to implantation challenges, large
imaging artefacts and the potential for dose perturbations in the target volumes [11,17,19,20,22].
Recently, a radio-opaque solid marker was used for image guidance in a mouse model of
radiation-induced intestinal damage [37]. However, this approach required surgical implantation into
the jejunum, with associated increased risk of adverse events in experimental mice.
An alternative strategy, more applicable to mouse models, is the use of injectable fiducial markers.
BioXmark® is a robust, radio-opaque injectable marker that has been clinically evaluated in multiple
indications including oesophageal, breast and lung cancers [25,38–41]. BioXmark® is composed of
biodegradable sucrose acetate isobutyrate (SAIB), an iodine contrast agent in an ethanol solvent which
diffuses out of the marker after being injected into soft tissue, increasing viscosity to form a radio-opaque,
semi-solid, gel-like marker [42]. In comparison to solid fiducial markers, this formulation can be
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injected at various volumes specific to individual patients [23,43]. A previous study demonstrated the
benefit of BioXmark® in an orthotopic pancreatic tumour model for improving soft tissue delineation,
repositioning and fusion of treatment plans [24]. However, detailed in phantom and in vivo imaging
analysis and characterisation of radiobiological response after the injection of BioXmark® are yet to
be reported.
In the current study, BioXmark® was shown to produce significantly reduced CBCT imaging
artefacts compared to solid gold- and polymer-based markers. Imaging artefacts produced by solid
markers negatively impact the visualisation of small structures which are important during SAIGRT.
However, volumes as small as 10µL of BioXmark® could equally enhance CBCT image contrast without
producing disruptive imaging artefacts and clearly enabled visualisation of anatomical structures in
small animals. In comparison to solid fiducial markers, the observed reduction in CBCT artefacts
for BioXmark® may also improve segmentation and uncertainty during dose calculation. From our
data, volumes of BioXmark® >60 µL caused imaging artefacts comparable to solid markers and are
unsuitable for SAIGRT.
In addition to image quality, several aspects need to be considered in the preclinical setting,
including stability, in vivo contrast enhancement and potential impacts on dose calculation. BioXmark®
was shown to be safe and stable in vivo when administered via subcutaneous and intratumoral injection
routes. It was also shown to be stable with minimal migration from the injection site for time periods
up to 5 months, again supporting its use in preclinical radiotherapy studies. These findings are
in agreement with previous reports of high tolerability and stability in mice up to 4 months after
injection [24].
Our data showed that BioXmark® may impact dose calculations when planning to use an
isocentre located within the injected fiducial volume. This caused BioXmark® to be recognised as a
high-Z material during dose calculation, resulting in observable differences in tumour growth delay.
These effects may be significant during radiobiological studies and could be minimised by removing
BioXmark® from the point-dose calculation. This could be achieved by injecting BioXmark® into
an adjacent peri-tumoral site or by placing the isocentre outside of the injected volume. In addition,
the observed limitations of BioXmark® highlight the need for robust imaging quality assurance that
can be achieved through the use of standardised imaging phantoms. Furthermore, advanced image
reconstruction techniques and imaging methods such as dual-energy CT (DECT) may also reduce
uncertainties [44]. Ultimately, Monte-Carlo-based treatment planning calculations may be more
appropriate when using BioXmark®, offering improved ability to segment multiple tissues based on
assumed atomic numbers calculated from CBCT images [45,46].
In this study, we presented the first data evaluating the effects of BioXmark® on tumour response
in vivo from both single and fractionated exposures. BioXmark® was shown to have no significant
impact on tumour growth in control animals. In irradiated animals, there was an observable but not
statistically significant difference in tumour growth delay, which was related to the number of fractions
delivered. We hypothesised that these variations were due to the high mass attenuation coefficient
assigned to the BioXmark® during dose calculation, resulting in underdosing of the adjacent tumour
tissue. Further investigation of the DVHs and contouring of BioXmark® in Muriplan confirmed these
findings and replanning of treatments lead to more accurate dose calculations.
4. Materials and Methods
4.1. Liquid Fiducial Marker
The novel liquid fiducial marker used in this study was BioXmark®, produced by Nanovi A/S
(Kongens Lyngby, Denmark). BioXmark® is a sterile, ready-to-inject fiducial maker composed
of biodegradable sucrose acetate isobutyrate (SAIB), iodinated SAIB and ethanol as a solvent.
This formulation ensures that when BioXmark® is injected into soft tissue, the ethanol partly diffuses
out of the marker, increasing the viscosity of the marker and resulting in the formation of a semi-solid
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gel [42]. Aspiration from the ampoule was completed using an 18 gauge needle and injection into in
phantom and in vivo models was done with a 25 gauge needle.
4.2. Solid Fiducial Markers
Commercially available gold (Gold AnchorTM, 0.4 mm in diameter and 3 mm in length) and
polymer (PolyMarkTM, 1 mm in diameter and 3 mm in length) fiducial markers were used to compare
in phantom imaging artefacts on CBCT imaging with BioXmark®.
4.3. Imaging and Irradiation
Mice were irradiated with 220 kVp X-rays under CBCT image guidance using a Small Animal
Radiation Research Platform (SARRP, Xstrahl Life Sciences, Camberley, UK) calibrated using the
Institute of Physics and Engineering in Medicine and Biology (IPEMB) code of practice [47], using
ionizing chambers and gafchromic film. The half-value layer (HVL) was 0.65 mm Cu with a 0.15 mm
Cu filter, for a 220 kV treatment beam with the dose rate quoted being the surface dose rate.
Mice were randomized prior to irradiation, with a single fraction dose of 16 Gy or fractionated
doses of 2 × 8 Gy or 4 × 4 Gy delivered using a parallel opposed, anterior-posterior beam geometry,
with equally weighted doses, with a 10 × 10 mm collimator (dose rate 2.67 ± 0.11 Gy/min for 34 cm SSD).
CBCT scans were performed before irradiation and DVHs calculated for each mouse using Muriplan
(Xstrahl Inc, Suwannee, GA, USA). Muriplan uses a heterogeneous superposition convolution dose
engine implemented on a graphics processing unit (GPU), and the quoted dose is the dose to medium.
The entire small animal treatment was controlled from the 3DSlicer-based user interface. The acquired
CBCT was transformed into material properties by defining five discrete windows for air, lung, fat,
tissue and bone (Table S2). The dose engine uses the absorption coefficients of these materials according
to the National Institute of Standards and Technology database [48].
4.4. In Phantom Studies
A 3D-printed phantom (4 × 4 × 4 cm) filled with gelatine from porcine skin (50 mg/mL,
Sigma-Aldrich Company, LTD, Dorset, UK) was used to replicate soft tissue. A layer of gelatine (1 cm)
was added to the phantom before and after the placement of each marker. The gold and polymer
fiducial markers were placed into the gelatine using tweezers and 20 µL of BioXmark® was injected
using a 25 gauge needle. Gelatin was set in the fridge for 1 h and then imaged using CBCT. Phantom
models were imaged twice at 40, 50 and 60 kV.
Artefact Analysis
CBCT scan slices were individually analysed using ImageJ software (http://imagej.nih.gov/ij).
The surrounding artefact area was determined by adjusting the threshold of images to highlight imaging
artefacts (black) from the background (white), and then utilising the ‘analyse particles’ function to
calculate the relative artefact area. Artefact area was measured in pixels (px), (1 px = 0.26 mm). For each
marker, CBCT scan slices covering each marker were combined and averaged. Scans were completed
twice at 40, 50 and 60 kV and results averaged for each.
4.5. In Vivo Studies
Tumour growth and stability were investigated in female 12–15-week old C57BL/6J mice obtained
from Charles River Laboratories (Oxford, UK). All mice were housed under controlled conditions
(12 h light–dark cycle, 21 ◦C) in standard caging with three to five littermates, and received a standard
laboratory diet and water ad libitum. To improve the welfare of mice, environmental enrichment
tools were placed in caging such as cardboard tubes for exploration, softwood blocks to encourage
gnawing to prevent tooth overgrowth, nesting material for comfort and mouse swings for added
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cage complexity and exercise. Mice were also handled gently and frequently from a young age to
reduce stress.
Prior to irradiation, animals were anaesthetised with ketamine and xylazine (100 mg/kg and
10 mg/kg) by intraperitoneal injection. All experimental procedures were carried out in accordance
with the Home Office Guidance on the Operation of the Animals (Scientific Procedures) Act 1986,
published by Her Majesty’s Stationary Office, London, and approved by the Queen’s University Belfast
Animal Welfare and Ethical Review Body (PPL2813). Animal studies are reported in compliance with
the ARRIVE guidelines [49].
4.5.1. In Vivo Stability
Mice were administered anaesthesia via intraperitoneal injection. Different volumes of BioXmark®
(10, 20 or 40 µL) were injected at two separate points on the flank (right and left) or one intraperitoneal
injection (40 µL) using a 25 G needle (n = 4). Mice were then imaged on CBCT at various time points
over a 5-month period. The weight and wellbeing of the mice was assessed weekly. The CBCT
value, migration and volume of BioXmark® visible on CBCT scans was assessed throughout the study.
Analysis was performed using Muriplan treatment planning software.
4.5.2. In Vivo Tumour Model
Tumour xenograft studies were performed using Lewis lung carcinoma (LLC) cells cultured in
DMEM media (+4.5 g/L D-glucose, L-glutamine, -pyruvate) supplemented with 10% foetal bovine
serum (FBS), 1% penicillin/streptomycin and 1 µM sodium pyruvate. Cells were maintained at 37 ◦C in
a humidified atmosphere of 5% CO2 and subcultured every 3–4 days to maintain exponential growth.
LLC cells were cultured in vitro and prepared in PBS (1 × 106 cells per 100 µL). Subsequently,
100 µL was injected subcutaneously into the flank of each C57BL/6 mouse (n = 48). Mice were
anesthetized using inhalant isoflurane for implant and placed in a heat box for recovery. Mice were
then returned to conventional housing and closely monitored.
Tumour volume was determined three times a week using calliper measurements in three
orthogonal dimensions. After tumour growth to a volume of 100 mm3, mice were randomly allocated
to one of the following subgroups: (i) control, (ii) control + BioXmark®, (iii) single dose: 16 Gy, (iv) single
dose: 16 Gy + BioXmark®, (v) fractionated dose: 2× 8 Gy, (vi) fractionated dose: 2 × 8 Gy + BioXmark®,
(vii) fractionated dose: 4 × 4 Gy, (viii) fractionated dose: 4 × 4 Gy + BioXmark®. An average of six mice
were allocated to each subgroup through randomisation. Mice were ear-punched for identification.
Intratumoral injection of 20 µL of BioXmark® was performed immediately prior to irradiation,
accounting for approximately 20% of the pre-treatment tumour volume. Experimental endpoints were
defined as tumour volume exceeding 500 mm3 (<GMD 12 mm) or loss of 15% body weight.
4.6. Statistical Analysis
Statistical differences between populations were calculated using unpaired two-tailed Student’s
t-tests, or one-way ANOVA tests where appropriate, with a significance threshold of p< 0.05 using Prism
GraphPad Prism 7 (Version 7.01, GraphPad Software, Inc., San Diego, CA, USA) (www.graphpad.com).
Data are presented as the average for the entire experimental arm ± SEM.
5. Conclusions
Our data further support the use of BioXmark® in preclinical imaging and SAIGRT applications,
based on reduced imaging artefacts with minimal impacts on tumour response. Alterations in
CT number due to BioXmark® should be carefully considered during dose calculations to ensure
homogeneity. BioXmark® is a useful tool for improving target definition and alignment protocols in
SAIGRT studies within the NC3Rs framework.
Cancers 2020, 12, 1276 12 of 14
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1276/s1.
Figure S1: In vivo stability of BioXmark® after intraperitoneal injection, Figure S2: Re-planned Dose Volume
Histogram (DVH) of an LLC tumour receiving single dose 16 Gy irradiation with an intra-tumoral injection
of BioXmark®, Table S1: Average CBCT values for air, tissue, bone and BioXmark for control and BioXmark
implanted mice, Table S2: Maximum values for segmentation windows for control and BioXmark implanted mice.
Author Contributions: Conceptualization, K.T.B., K.M.P. and G.S.; Methodology and formal analysis, K.H.B.,
M.G. and K.T.B.; Writing original draft preparation K.H.B., M.G. and K.T.B. All authors have read and agreed to
the published version of the manuscript.
Funding: K.H.B. is supported by a training Fellowship from the National Centre for the Replacement, Refinement
and Reduction of Animals in Research (Grant Number NC/R001553/1). M.G., K.M.P. and K.T.B. gratefully
knowledge support from the Tom Simms Memorial Fund, Friends of the Cancer Centre and the Queen’s
University Foundation.
Acknowledgments: The authors wish to acknowledge close collaboration and input from Jesper Boysen and
Michael Wrang Mortensen (Nanovi A/S, Denmark).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Jolck, R.I.; Rydhog, J.S.; Christensen, A.N.; Hansen, A.E.; Bruun, L.M.; Schaarup-Jensen, H.; von Wenck, A.S.;
Borresen, B.; Kristensen, A.T.; Clausen, M.H.; et al. Injectable colloidal gold for use in intrafractional 2D
image-guided radiation therapy. Adv. Healthc. Mater. 2015, 4, 856–863. [CrossRef] [PubMed]
2. Hussein, M.; Heijmen, B.J.M.; Verellen, D.; Nisbet, A. Automation in intensity modulated radiotherapy
treatment planning—A review of recent innovations. Br. J. Radiol. 2018, 91, 20180270. [CrossRef] [PubMed]
3. Miles, E.A.; Clark, C.H.; Urbano, M.T.G.; Bidmead, M.; Dearnaley, D.P.; Harrington, K.J.; A’Hern, R.;
Nutting, C.M. The impact of introducing intensity modulated radiotherapy into routine clinical practice.
Radiother. Oncol. 2005, 77, 241–246. [CrossRef] [PubMed]
4. Dahele, M.; Mclaren, D.B. Stereotactic body radiotherapy. Clin. Oncol. 2015, 27, 249–250. [CrossRef]
[PubMed]
5. Butterworth, K.T. Evolution of the supermodel: Progress in modelling radiotherapy response in mice.
Clin. Oncol. R. Coll. Radiol. 2019, 31, 272–282. [CrossRef] [PubMed]
6. Goyal, S.; Kataria, T. Image guidance in radiation therapy: Techniques and applications. Radiol. Res. Pract.
2014, 2014, 1–10. [CrossRef]
7. Bedford, J.L.; Chajecka-Szczygielska, H.; Thomas, M.D.R. Quality control of VMAT synchronization using
portal imaging. J. Appl. Clin. Med. Phys. 2015, 16, 284–297. [CrossRef]
8. Bell, K.; Heitfeld, M.; Licht, N.; Rübe, C.; Dzierma, Y. Influence of daily imaging on plan quality and normal
tissue toxicity for prostate cancer radiotherapy. Radiat. Oncol. 2017, 12, 1–11. [CrossRef]
9. Liney, G.P.; Whelan, B.; Oborn, B.; Barton, M.; Keall, P. MRI-linear accelerator radiotherapy systems.
Clin. Oncol. 2018, 30, 686–691. [CrossRef]
10. Habermehl, D.; Henkner, K.; Ecker, S.; Jakel, O.; Debus, J.; Combs, S.E. Evaluation of different fiducial
markers for image-guided radiotherapy and particle therapy. J. Radiat. Res. 2013, 54, i61–i68. [CrossRef]
11. O’Neill, A.G.M.; Jain, S.; Hounsell, A.R.; O’Sullivan, J.M. Fiducial marker guided prostate radiotherapy:
A review. Br. J. Radiol. 2016, 89, 20160296. [CrossRef]
12. Fernandez, D.C.; Hoffe, S.E.; Barthel, J.S.; Vignesh, S.; Klapman, J.B.; Harris, C.; Almhanna, K.; Biagioli, M.C.;
Meredith, K.L.; Feygelman, V.; et al. Stability of endoscopic ultrasound-guided fiducial marker placement
for esophageal cancer target delineation and image-guided radiation therapy. Pract. Radiat. Oncol. 2013, 3,
32–39. [CrossRef] [PubMed]
13. DiMaio, C.J.; Nagula, S.; Goodman, K.A.; Ho, A.Y.; Markowitz, A.J.; Schattner, M.A.; Gerdes, H. EUS-guided
fiducial placement for image-guided radiation therapy in GI malignancies by using a 22-gauge needle (with
videos). Gastrointest. Endosc. 2010, 71, 1204–1210. [CrossRef] [PubMed]
14. Jin, P.; van der Horst, A.; de Jong, R.; van Hooft, J.E.; Kamphuis, M.; van Wieringen, N.; Machiels, M.; Bel, A.;
Hulshof, M.C.C.M.; Alderliesten, T. Marker-based quantification of interfractional tumor position variation
and the use of markers for setup verification in radiation therapy for esophageal cancer. Radiother. Oncol.
2015, 117, 412–418. [CrossRef] [PubMed]
Cancers 2020, 12, 1276 13 of 14
15. van der Heide, U.A.; Kotte, A.N.T.J.; Dehnad, H.; Hofman, P.; Lagenijk, J.J.W.; van Vulpen, M. Analysis
of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate
cancer. Radiother. Oncol. 2007, 82, 38–45. [CrossRef]
16. Rydhög, J.S.; Jølck, R.I.; Andresen, T.L.; Munck Af Rosenschöld, P. Quantification and comparison of visibility
and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy.
Med. Phys. 2015, 42, 2818–2826. [CrossRef] [PubMed]
17. Gurney-Champion, O.J.; Lens, E.; Van Der Horst, A.; Houweling, A.C.; Klaassen, R.; Van Hooft, J.E.; Stoker, J.;
Van Tienhoven, G.; Nederveen, A.J.; Bel, A. Visibility and artifacts of gold fiducial markers used for image
guided radiation therapy of pancreatic cancer on MRI. Med. Phys. 2015, 42, 2638–2647. [CrossRef]
18. Schneider, S.; Jolck, R.I.; Troost, E.G.C.; Hoffmann, A.L. Quantification of MRI visibility and artifacts at 3T of
liquid fiducial marker in a pancreas tissue-mimicking phantom. Med. Phys. 2018, 45, 37–47. [CrossRef]
19. Osman, S.O.S.; Russell, E.; King, R.B.; Crowther, K.; Jain, S.; McGrath, C.; Hounsell, A.R.; Prise, K.M.;
McGarry, C.K. Fiducial markers visibility and artefacts in prostate cancer radiotherapy multi-modality
imaging. Radiat. Oncol. 2019, 14, 237. [CrossRef]
20. Slagowski, J.M.; Colbert, L.E.; Cazacu, I.M.; Singh, B.S.; Martin, R.; Koay, E.J.; Taniguchi, C.M.; Koong, A.C.;
Bhutani, M.S.; Herman, J.M.; et al. Evaluation of the visibility and artifacts of 11 common fiducial markers
for image guided stereotactic body radiation therapy in the abdomen. Pract. Radiat. Oncol. 2020. [CrossRef]
21. Chan, M.F.; Cohen, G.N.; Deasy, J.O. Qualitative evaluation of fiducial markers for radiotherapy imaging.
Technol. Cancer Res. Treat. 2015, 14, 298–304. [CrossRef] [PubMed]
22. Scherman Rydhög, J.; Perrin, R.; Jølck, R.I.; Gagnon-Moisan, F.; Larsen, K.R.; Clementsen, P.;
Riisgaard de Blanck, S.; Fredberg Persson, G.; Weber, D.C.; Lomax, T.; et al. Liquid fiducial marker
applicability in proton therapy of locally advanced lung cancer. Radiother. Oncol. 2017, 122, 393–399.
[CrossRef]
23. De Roover, R.; Crijns, W.; Poels, K.; Peeters, R.; Draulans, C.; Haustermans, K.; Depuydt, T. Characterization
of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate
cancer. Med. Phys. 2018, 45, 2205–2217. [CrossRef]
24. Dobiasch, S.; Kampfer, S.; Burkhardt, R.; Schilling, D.; Schmid, T.E.; Wilkens, J.J.; Combs, S.E. BioXmark
for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid
fiducial marker. Strahlenther. Onkol. 2017, 193, 1039–1047. [CrossRef] [PubMed]
25. Machiels, M.; Voncken, F.E.M.; Jin, P.; van Dieren, J.M.; Bartels-Rutten, A.; Alderliesten, T.; Aleman, B.M.P.;
van Hooft, J.E.; Hulshof, M.C.C.M. A novel liquid fiducial marker in esophageal cancer image guided
radiation therapy: Technical feasibility and visibility on imaging. Pract. Radiat. Oncol. 2019, 9, e506–e515.
[CrossRef] [PubMed]
26. Citrin, D.E.; Mitchell, J.B. Mechanisms of normal tissue injury from irradiation. Semin. Radiat. Oncol. 2017,
27, 316–324. [CrossRef] [PubMed]
27. Booth, C.; Tudor, G.; Tudor, J.; Katz, B.P.; MacVittie, T.J. Acute gastrointestinal syndrome in high-dose
irradiated mice. Health Phys. 2012, 103, 383–399. [CrossRef]
28. Ghita, M.; Brown, K.H.; Kelada, O.J.; Graves, E.E.; Butterworth, K.T. Integrating small animal irradiators
withfunctional imaging for advanced preclinical radiotherapy research. Cancers 2019, 11, 170. [CrossRef]
29. Schulze, R.; Heil, U.; Groß, D.; Bruellmann, D.D.; Dranischnikow, E.; Schwanecke, U.; Schoemer, E. Artefacts
in CBCT: A review. Dentomaxillofacial Radiol. 2011, 40, 265–273. [CrossRef]
30. Broder, J. Diagnostic imaging for the emergency physician. In Diagnostic Imaging for the Emergency Physician;
Saunders: Centennial, CO, USA, 2011; pp. 445–577, ISBN 978-1-4160-6113-7.
31. Schneider, S.; Aust, D.E.; Bruckner, S.; Welsch, T.; Hampe, J.; Troost, E.G.C.; Hoffmann, A.L. Detectability and
structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT
and 3T MRI. Strahlenther. Onkol. 2019, 195, 756–763. [CrossRef]
32. Verhaegen, F.; Granton, P.; Tryggestad, E. Small animal radiotherapy research platforms. Phys. Med. Biol.
2011, 56, R55–R83. [CrossRef] [PubMed]
33. Biglin, E.R.; Price, G.J.; Chadwick, A.L.; Aitkenhead, A.H.; Williams, K.J.; Kirkby, K.J. Preclinical dosimetry:
Exploring the use of small animal phantoms. Radiat. Oncol. 2019, 14, 134. [CrossRef] [PubMed]
34. Koontz, B.F.; Verhaegen, F.; De Ruysscher, D. Tumour and normal tissue radiobiology in mouse models:
How close are mice to mini-humans? Br. J. Radiol. 2017, 90, 20160441. [CrossRef]
Cancers 2020, 12, 1276 14 of 14
35. Butterworth, K.T.; Prise, K.M.; Verhaegen, F. Small animal image-guided radiotherapy: Status, considerations
and potential for translational impact. Br. J. Radiol. 2015, 88, 20140634. [CrossRef]
36. Draeger, E.; Sawant, A.; Johnstone, C.; Koger, B.; Becker, S.; Vujaskovic, Z.; Jackson, I.L.; Poirier, Y. A dose
of reality: How 20 years of incomplete physics and dosimetry reporting in radiobiology studies may have
contributed to the reproducibility crisis. Int. J. Radiat. Oncol. Biol. Phys. 2020, 106, 243–252. [CrossRef]
[PubMed]
37. Verginadis, I.I.; Kanade, R.; Bell, B.; Koduri, S.; Ben-Josef, E.; Koumenis, C. A novel mouse model to study
image-guided, radiation-induced intestinal injury and preclinical screening of radioprotectors. Cancer Res.
2017, 77, 908–917. [CrossRef] [PubMed]
38. Ciernik, I.F.; Greiss, A.M. Visualization of the tumor cavity after lumpectomy of breast cancer for postoperative
radiotherapy. Clin. Transl. Radiat. Oncol. 2019, 14, 47–50. [CrossRef] [PubMed]
39. de Blanck, S.R.; Scherman-Rydhog, J.; Siemsen, M.; Christensen, M.; Baeksgaard, L.; Irming Jolck, R.;
Specht, L.; Andresen, T.L.; Persson, G.F. Feasibility of a novel liquid fiducial marker for use in image guided
radiotherapy of oesophageal cancer. Br. J. Radiol. 2018, 91, 20180236. [CrossRef]
40. Rydhög, J.S.; Mortensen, S.R.; Larsen, K.R.; Clementsen, P.; Jølck, R.I.; Josipovic, M.; Aznar, M.C.; Specht, L.;
Andresen, T.L.; Rosenschöld, P.M.; et al. Liquid fiducial marker performance during radiotherapy of locally
advanced non small cell lung cancer. Radiother. Oncol. 2016, 121, 64–69. [CrossRef]
41. de Blanck, S.R.; Rydhog, J.S.; Larsen, K.R.; Clementsen, P.F.; Josipovic, M.; Aznar, M.C.; Rosenschold, P.M.;
Jolck, R.I.; Specht, L.; Andresen, T.L.; et al. Long term safety and visibility of a novel liquid fiducial marker
for use in image guided radiotherapy of non-small cell lung cancer. Clin. Transl. Radiat. Oncol. 2018, 13,
24–28. [CrossRef]
42. Nanovi(A/S). BioXmark. Available online: http://nanovi.com/bioxmark/ (accessed on 5 December 2018).
43. Bertholet, J.; Knopf, A.; Mcclelland, J.; Grimwood, A. Real-time intrafraction motion monitoring in external
beam radiotherapy. Phys. Med. Biol. 2019, 64, 15TR01. [CrossRef] [PubMed]
44. Vaniqui, A.; Schyns, L.E.J.R.; Almeida, I.P.; Van Der Heyden, B.; Podesta, M.; Verhaegen, F. The effect of
different image reconstruction techniques on pre-clinical quantitative imaging and dual-energy cT. Br. J.
Radiol. 2019, 92, 20180447. [CrossRef] [PubMed]
45. Bazalova, M.; Zhou, H.; Keall, P.J.; Graves, E.E. Kilovoltage beam Monte Carlo dose calculations in
submillimeter voxels for small animal radiotherapy. Med. Phys. 2009, 36, 4991–4999. [CrossRef] [PubMed]
46. Van Hoof, S.J.; Granton, P.V.; Verhaegen, F. Development and validation of a treatment planning system for
small animal radiotherapy: SmART-Plan. Radiother. Oncol. 2013, 109, 361–366. [CrossRef]
47. Rosser, K.E. The IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV
generating potential (0.035 mm Al-4 mm Cu HVL; 10-300 kV generating potential). Phys. Med. Biol. 1996, 41,
2605–2625.
48. Hubbell, J.H.; Seltzer, S.M. X-ray mass attenuation coefficients. Radiat. Phys. Div. PML NIST 2004. [CrossRef]
49. McGrath, J.C.; Lilley, E. Implementing guidelines on reporting research using animals (ARRIVE etc.): New
requirements for publication in BJP. Br. J. Pharmacol. 2015, 172, 3189–3193. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
